These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 34461216)
1. Sequential administration of PEG-Span 80 niosome enhances anti-tumor effect of doxorubicin-containing PEG liposome. Minamisakamoto T; Nishiguchi S; Hashimoto K; Ogawara KI; Maruyama M; Higaki K Eur J Pharm Biopharm; 2021 Dec; 169():20-28. PubMed ID: 34461216 [TBL] [Abstract][Full Text] [Related]
2. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy. Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944 [TBL] [Abstract][Full Text] [Related]
3. Enhancement of antitumor effect of doxorubicin by its complexation with gamma-cyclodextrin in pegylated liposomes. Arima H; Hagiwara Y; Hirayama F; Uekama K J Drug Target; 2006 May; 14(4):225-32. PubMed ID: 16777681 [TBL] [Abstract][Full Text] [Related]
5. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells. Ogawara K; Un K; Tanaka K; Higaki K; Kimura T J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484 [TBL] [Abstract][Full Text] [Related]
6. A Novel Long-circulating DOX Liposome: Formulation and Pharmacokinetics Studies. Xiao P; Zhao J; Huang Y; Jin R; Tang Z; Wang P; Song X; Zhu H; Yang Z; Yu N Pharm Nanotechnol; 2020; 8(5):391-398. PubMed ID: 32787769 [TBL] [Abstract][Full Text] [Related]
7. Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors. Ogawara K; Un K; Minato K; Tanaka K; Higaki K; Kimura T Int J Pharm; 2008 Jul; 359(1-2):234-40. PubMed ID: 18448289 [TBL] [Abstract][Full Text] [Related]
8. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782 [TBL] [Abstract][Full Text] [Related]
9. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo. Sun M; Wang Y; Shen J; Xiao Y; Su Z; Ping Q Nanotechnology; 2010 Nov; 21(47):475101. PubMed ID: 21030757 [TBL] [Abstract][Full Text] [Related]
10. Effect of Doxorubicin Release Rate From Polyethylene Glycol-Modified Liposome on Anti-tumor Activity in B16-BL6 Tumor-Bearing Mice. Maruyama M; Tojo H; Toi K; Ienaka Y; Hyodo K; Kikuchi H; Ogawara KI; Higaki K J Pharm Sci; 2022 Feb; 111(2):293-297. PubMed ID: 34861247 [TBL] [Abstract][Full Text] [Related]
11. Effects of Surface Charge, PEGylation and Functionalization with Dipalmitoylphosphatidyldiglycerol on Liposome-Cell Interactions and Local Drug Delivery to Solid Tumors via Thermosensitive Liposomes. Petrini M; Lokerse WJM; Mach A; Hossann M; Merkel OM; Lindner LH Int J Nanomedicine; 2021; 16():4045-4061. PubMed ID: 34163158 [TBL] [Abstract][Full Text] [Related]
12. [Targeting therapy of magnetic doxorubicin liposome in nude mice bearing colon cancer]. Zhou PH; Yao LQ; Qin XY; Shen XZ; Liu YS; Lu WY; Yao M Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2073-6. PubMed ID: 14703420 [TBL] [Abstract][Full Text] [Related]
13. [Characterization and cytotoxicity of mixed PEG-DSG modified liposomes]. Sadzuka Y; Tsuruda T; Sonobe T Yakugaku Zasshi; 2005 Jan; 125(1):149-57. PubMed ID: 15635286 [TBL] [Abstract][Full Text] [Related]
14. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors. Kibria G; Hatakeyama H; Sato Y; Harashima H Int J Pharm; 2016 Jul; 509(1-2):178-187. PubMed ID: 27234700 [TBL] [Abstract][Full Text] [Related]
15. PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma. Xiao K; Luo J; Li Y; Lee JS; Fung G; Lam KS J Control Release; 2011 Oct; 155(2):272-81. PubMed ID: 21787818 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Huang SK; Mayhew E; Gilani S; Lasic DD; Martin FJ; Papahadjopoulos D Cancer Res; 1992 Dec; 52(24):6774-81. PubMed ID: 1458465 [TBL] [Abstract][Full Text] [Related]
17. The impact of phospholipids with high transition temperature to enhance redox-sensitive liposomal doxorubicin efficacy in colon carcinoma model. Mirhadi E; Askarizadeh A; Farhoudi L; Mashreghi M; Behboodifar S; Alavizadeh SH; Arabi L; Jaafari MR Chem Phys Lipids; 2024 Jul; 261():105396. PubMed ID: 38621603 [TBL] [Abstract][Full Text] [Related]
18. Sustained liver targeting and improved antiproliferative effect of doxorubicin liposomes modified with galactosylated lipid and PEG-lipid. Wang S; Xu H; Xu J; Zhang Y; Liu Y; Deng YH; Chen D AAPS PharmSciTech; 2010 Jun; 11(2):870-7. PubMed ID: 20490957 [TBL] [Abstract][Full Text] [Related]
19. Dual-effect liposomes encapsulated with doxorubicin and chlorin e6 augment the therapeutic effect of tumor treatment. Peng PC; Hong RL; Tsai YJ; Li PT; Tsai T; Chen CT Lasers Surg Med; 2015 Jan; 47(1):77-87. PubMed ID: 25559348 [TBL] [Abstract][Full Text] [Related]
20. Doxorubicin Loaded Silica Nanoparticles with Dual Modification as a Tumor-Targeted Drug Delivery System for Colon Cancer Therapy. Lin YQ; Zhang J; Liu SJ; Ye H J Nanosci Nanotechnol; 2018 Apr; 18(4):2330-2336. PubMed ID: 29442900 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]